肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

港中大教授获肿瘤学会颁终身成就奖 成首位获奖华人

2018-11-02 大公报 大公报

莫树锦终身成就奖
关注

莫树锦获ESMO颁发终身成就奖 （ESMO官网）香港中文大学医学院肿瘤学系系主任莫树锦近日获欧洲肿瘤学会(ESMO)颁发“终身成就奖”，表彰他是全球第一人把“个人化治疗”概念应用在晚期肺癌患者身上，改变了肺癌治疗规范。莫树锦多年来致力肺癌生物标记的研究，多项研究均处于世界领先地位。莫树锦于2009年发表的研究确认，有“基因变异”的癌症病人更适合接受标靶治疗，提供了肺癌治疗的新方向。医生可据此针对不



莫树锦获ESMO颁发终身成就奖 （ESMO官网）

香港中文大学医学院肿瘤学系系主任莫树锦近日获欧洲肿瘤学会(ESMO)颁发“终身成就奖”，表彰他是全球第一人把“个人化治疗”概念应用在晚期肺癌患者身上，改变了肺癌治疗规范。

莫树锦多年来致力肺癌生物标记的研究，多项研究均处于世界领先地位。莫树锦于2009年发表的研究确认，有“基因变异”的癌症病人更适合接受标靶治疗，提供了肺癌治疗的新方向。医生可据此针对不同的基因变异为病人订造治疗方案，实现“个人化治疗”。

正在德国慕尼黑举行会议的ESMO是全球最大癌症医学会之一，莫树锦则是首位获ESMO颁发终身成就奖的华人，并被誉为“肿瘤学界传奇”。他在获奖后表示，“我要为病人创造希望，与战友一起，向肺癌宣战”。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1763995, encodeId=f9321e639952f, content=<a href='/topic/show?id=ecf88800939' target=_blank style='color:#2F92EE;'>#获奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88009, encryptionId=ecf88800939, topicName=获奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d5937606588, createdName=若水135, createdTime=Mon Aug 19 04:34:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390778, encodeId=65931390e7817, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sun Nov 04 05:34:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582028, encodeId=e86e15820280a, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Sun Nov 04 05:34:00 CST 2018, time=2018-11-04, status=1, ipAttribution=)]
    2019-08-19 若水135

    #获奖#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1763995, encodeId=f9321e639952f, content=<a href='/topic/show?id=ecf88800939' target=_blank style='color:#2F92EE;'>#获奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88009, encryptionId=ecf88800939, topicName=获奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d5937606588, createdName=若水135, createdTime=Mon Aug 19 04:34:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390778, encodeId=65931390e7817, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sun Nov 04 05:34:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582028, encodeId=e86e15820280a, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Sun Nov 04 05:34:00 CST 2018, time=2018-11-04, status=1, ipAttribution=)]
    2018-11-04 108807375_62823127

    #肿瘤学#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1763995, encodeId=f9321e639952f, content=<a href='/topic/show?id=ecf88800939' target=_blank style='color:#2F92EE;'>#获奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88009, encryptionId=ecf88800939, topicName=获奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d5937606588, createdName=若水135, createdTime=Mon Aug 19 04:34:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390778, encodeId=65931390e7817, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sun Nov 04 05:34:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582028, encodeId=e86e15820280a, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Sun Nov 04 05:34:00 CST 2018, time=2018-11-04, status=1, ipAttribution=)]
    2018-11-04 ms4468361851264128

    #华人#

    0